GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » PB Ratio

Glenmark Pharmaceuticals (NSE:GLENMARK) PB Ratio : 3.19 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Glenmark Pharmaceuticals's share price is ₹1053.30. Glenmark Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was ₹330.55. Hence, Glenmark Pharmaceuticals's PB Ratio of today is 3.19.

The historical rank and industry rank for Glenmark Pharmaceuticals's PB Ratio or its related term are showing as below:

NSE:GLENMARK' s PB Ratio Range Over the Past 10 Years
Min: 0.99   Med: 2.94   Max: 8.9
Current: 3.19

During the past 13 years, Glenmark Pharmaceuticals's highest PB Ratio was 8.90. The lowest was 0.99. And the median was 2.94.

NSE:GLENMARK's PB Ratio is ranked worse than
71.56% of 960 companies
in the Drug Manufacturers industry
Industry Median: 1.97 vs NSE:GLENMARK: 3.19

During the past 12 months, Glenmark Pharmaceuticals's average Book Value Per Share Growth Rate was -2.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 16.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 12.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 13.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Glenmark Pharmaceuticals was 63.90% per year. The lowest was 5.30% per year. And the median was 14.10% per year.

Back to Basics: PB Ratio


Glenmark Pharmaceuticals PB Ratio Historical Data

The historical data trend for Glenmark Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals PB Ratio Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 0.96 1.86 1.37 1.38

Glenmark Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.38 - 2.59 -

Competitive Comparison of Glenmark Pharmaceuticals's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's PB Ratio falls into.



Glenmark Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Glenmark Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1053.30/330.551
=3.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Glenmark Pharmaceuticals  (NSE:GLENMARK) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Glenmark Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines